Adrenomedullin for assessing congestion in a subject with acute heart failure

A method for

• a) diagnosing congestion or assessing or monitoring the extent of congestion in a subject or,
• b) predicting or determining or monitoring need of therapy or intervention of congestion or predicting or determining or monitoring the success of a therapy or intervention of congestion or guiding a therapy or intervention of congestion in a subject or,
• c) predicting decongestion or residual congestion after therapy or intervention of congestion in a subject or,
• d) assessing decongestion or residual congestion after therapy or intervention of congestion in a subject or,
• e) assessing the decision on hospital discharge of a subject,
• wherein said subject is subject having acute heart failure that is either new-onset AHF or acute decompensated HF or acute decompensated chronic HF or wherein said subject is a subject having chronic heart failure with worsening signs/symptoms of chronic heart failure and
• wherein Pro-Adrenomedullin or fragments thereof of at least 5 amino acids is used as an early surrogate marker for congestion and
• wherein said Pro-Adrenomedullin or fragment is selected from the group comprising Pro-Adrenomedullin according to SEQ ID No. 1 or PAMP according to SEQ ID No.:
• 2 or MR-proADM according to SEQ ID No.:
• 3 or mature ADM-NH2 according to SEQ ID No.:
• 4 or ADM-Gly according to SEQ ID No.:
• 5 or CT-proADM according to SEQ ID No.:
• 6.